Sailesh Raj Bhan on what to do with IT and pharma stocks now

The IT sector is experiencing slower growth rates, which could lead to a correction in the current 20-multiple valuation of these businesses. However, the sector still has a long-term growth opportunity, especially in the domestic branded space. In pharma, the domestic branded space still has a meaningful decades-long growth opportunity and that is where our focus should be .